



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 9/00, A61K 38/14, C07H 3/06, A61K 31/70</b>		A1	(11) International Publication Number: <b>WO 99/65934</b>
			(43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/EP99/04100 (22) International Filing Date: 11 June 1999 (11.06.99) (30) Priority Data: 98202037.2                  17 June 1998 (17.06.98)                  EP (71) Applicants (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). UNIVERSITEIT LEIDEN [NL/NL]; Rapenburg 70, NL-2311 EZ Leiden (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): BASTEN, Johannes, Egbertus, Maria [NL/NL]; St. Victorstraat 41, NL-6654 AV Afferden (NL). VAN BOECKEL, Constant, Adriaan, Anton [NL/NL]; Mercuriusstraat 32, NL-5345 LX Oss (NL). BUIJSMAN, Rogier, Christian [NL/NL]; St. Anthoniusstraat 26, NL-5341 LD Oss (NL). DREEF-TROMP, Cornelia, Maria [NL/NL]; Sluiskamp 31-62, NL-6605 SN Wijchen (NL). (74) Agent: HOGENBIRK, M.; P.O. Box 20, NL-5340 BH Oss (NL).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published With international search report.	
(54) Title: ANTITHROMBOTIC COMPOUNDS			
<div style="text-align: center;"> <math display="block">\begin{array}{c} \text{Z} \\   \\ \text{Q} \\   \\ \text{R}^1\text{-S(O)}_2\text{-N(H)-C(H)-C(O)-N(R}^2\text{)-C(H)-C(O)-NR}^3\text{R}^4 \end{array}</math> <p>(I)</p> </div>			
(57) Abstract			
<p>The present invention relates to compounds of formula (I), wherein R<sup>1</sup> is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy; R<sup>2</sup> and R<sup>3</sup> are independently H or (1-8C)alkyl; R<sup>4</sup> is (1-8C)alkyl or (3-8C)cycloalkyl; or R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom to which they are bonded are a nonaromatic (4-8)membered ring optionally containing another heteroatom, the ring optionally being substituted with (1-8C)alkyl or SO<sub>2</sub>-(1-8C)alkyl; Q is a spacer having a chain length of 10 to 70 atoms; and Z is a negatively charged oligosaccharide residue comprising two to six monosaccharide units, the charge being compensated by positively charged counterions; or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombin-related diseases.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ANTITHROMBOTIC COMPOUNDS

The invention relates to new antithrombotic agents, a process for their preparation,  
5 pharmaceutical compositions containing the compounds as active ingredients, as well as the use  
of said compounds for the manufacture of medicaments.

Serine proteases are enzymes which play an important role in the blood coagulation cascade.  
Members of this group of proteases are for example thrombin, trypsin, factors VIIa, IXa, Xa,  
10 XIa, XIIa, and protein C.


Thrombin is the final serine protease enzyme in the coagulation cascade. The prime function of  
thrombin is the cleavage of fibrinogen to generate fibrin monomers, which are cross-linked to  
form an insoluble gel. In addition, thrombin regulates its own production by activation of factors  
V and VIII earlier in the cascade. It also has important actions at cellular level, where it acts on  
15 specific receptors to cause platelet aggregation, endothelial cell activation and fibroblast  
proliferation. Thus thrombin has a central regulatory role in haemostasis and thrombus  
formation. Since inhibitors of thrombin may have a wide range of therapeutical applications,  
extensive research is done in this area.

Another important serine protease, factor Xa, catalyzes the conversion of prothrombin into  
20 thrombin.

In the development of synthetic inhibitors of serine proteases, and more specifically of thrombin,  
the benzamidine moiety is one of the key structures. It mimics the protonated side-chain of the  
basic amino acids Arg and Lys of its natural substrates. Compounds with this moiety have been  
25 studied extensively and repeatedly. A very potent representative of this type of thrombin  
inhibitors is the amino acid derivative N $\alpha$ -(2-naphthylsulfonyl)-glycyl-4-amidinophenylalanin-  
piperidide (NAPAP) (Stürzebecher, J. et al., Thromb. Res. **29**, 635-642, 1983). However, the  
profile of NAPAP is unattractive for therapeutical applications: for example, the compound has  
low thrombin specificity and is poorly soluble. Derivatives of NAPAP were subsequently  
30 prepared, such as the N-alkyl substituted derivatives disclosed in EP 0,236,163 or the  
glycopeptide derivatives described EP 0,558,961, Proc. Am. Pept. Symp., 13th (60LXAW); 94;

pp. 643-5 (Stüber, W. et al., Pept.: Chem., Struct. Biol.), Proc. Int. Symp. Controlled Release Bioact. Mater. (PCRMEY, 10220178); 94; Vol. 21 st; pp. 712-12 (Walter, E. et al.), and EP 0,513,543. However, although these derivatizations may have led to improvements of the pharmacological profile when compared to NAPAP, all such NAPAP-derived compounds are still active only as direct thrombin inhibitors and they have a restricted plasma half-life and a fast clearance (thus displaying their anti-thrombin activity only for a short period of time).

It has now been found that compounds of the formula (I)



wherein  $\text{R}^1$  is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy;

$\text{R}^2$  and  $\text{R}^3$  are independently H or (1-8C)alkyl;

$\text{R}^4$  is (1-8C)alkyl or (3-8C)cycloalkyl;

or  $\text{R}^3$  and  $\text{R}^4$  together with the nitrogen atom to which they are bonded are a nonaromatic (4-8)membered ring optionally containing another heteroatom, the ring optionally being substituted with (1-8C)alkyl or  $\text{SO}_2$ -(1-8C)alkyl;

Q is a spacer having a chain length of 10 to 70 atoms; and

Z is a negatively charged oligosaccharide residue comprising two to six monosaccharide units, the charge being compensated by positively charged counterions;

or a pharmaceutically acceptable salt thereof or a prodrug thereof are potent and highly versatile antithrombotics. The compounds of the invention have anti-thrombin activity, but also the structure of the compounds may be selectively modified so that they have a tuneable mixed profile of both non-mediated, direct anti-thrombin (factor IIa) activity and anti-thrombin III

(AT-III) mediated anti-Xa activity. The compounds of the invention thus are dual inhibitors. Compounds of the invention have a long plasma half-life and, as a result, they possess prolonged anti-thrombin activity compared to NAPAP or its above reported derivatives. Further, compounds of the invention may escape the neutralizing action of platelet factor 4 (PF4). Low toxicity is also an advantageous aspect of compounds of this invention.

Another type of dual inhibitors is disclosed in EP 0,649,854. Contrary to the compounds of the present invention the conjugated saccharide compounds disclosed in that document display *indirect*, AT-III mediated anti-thrombin activity, in addition to AT-III mediated anti-Xa activity.

10

The compounds of the present invention are useful for treating and preventing thrombin-mediated and thrombin-associated diseases. This includes a number of thrombotic and prothrombotic states in which the coagulation cascade is activated which include, but are not limited to, deep vein thrombosis, pulmonary embolism, thrombophlebitis, arterial occlusion from thrombosis or embolism, arterial reocclusion during or after angioplasty or thrombolysis, restenosis following arterial injury or invasive cardiological procedures, postoperative venous thrombosis or embolism, acute or chronic atherosclerosis, stroke, myocardial infarction, cancer and metastasis, and neurodegenerative diseases. The compounds of the invention may also be used as anticoagulants in extracorporeal blood circuits, as necessary in dialysis and surgery.

20

The compounds of the invention may also be used as *in vitro* anticoagulants.


The mixed profile of the compounds of the invention may be tuned by varying the nature of the oligosaccharide residue Z and the length of the spacer Q. A range of profiles is thereby available.

25

Any negatively charged oligosaccharide residue of 2 to 6 saccharide units is useable in the compounds of the present invention. Suitable compounds of the invention are compounds wherein Z is a sulfated or phosphorylated oligosaccharide residue. Preferably, the oligosaccharide residue Z is derived from an oligosaccharide which has *per se* AT-III mediated anti-Xa activity, such as the saccharides disclosed in EP 0,454,220 and EP 0,529,715.

30

Particularly preferred oligosaccharide residues are pentasaccharide residues. Most preferably, Z has the formula (II)




wherein  $R^5$  is independently  $OSO_3^-$  or (1-8C)alkoxy.

Further preferred compounds of the invention are compounds of formula I, wherein  $R^1$  is phenyl,  
 5 4-methoxy-2,3,6-trimethylphenyl or naphthyl. In preferred compounds,  $NR^3R^4$  represents the piperidinyll group. Preferably,  $R^2$  is H.

The chemical structure of the spacer is of minor or no importance for the anti-thrombotic activity  
 of the compounds of the invention, it may however not be completely rigid. Highly flexible  
 10 spacers are more suitable than others.

Further, for synthetic reasons some spacers are more appropriate than others.

Suitable spacers that can easily be used have for example the formula (III):



15

wherein

W is  $-[1,4\text{-phenylene-}NR^3-C(O)]_q-(CH_2)_r-S-$

or

$-(CH_2)_t-S-(CH_2)_u-[O(CH_2)_2]_v-O-(CH_2)_w-C(O)-NR^3-$ ;

20

and  $R^3$  is independently H or (1-8C)alkyl;

$m = 1 - 12$ ;  $n = 1 - 8$ ;  $p = 0 - 4$ ;  $q = 0$  or  $1$ ;  $r = 1 - 8$ ;  $s = 1 - 8$ ;  $t = 1 - 8$ ;  $u = 1 - 8$ ;  $v = 1 - 12$ ;  $w =$   
 $1 - 8$ ; the total number of atoms is  $10 - 70$ ; and the moiety  $-[(CH_2)_2O]_m-$  is the end with which Q  
 is attached to Z.

25

Preferred spacers are the following:



-[(CH<sub>2</sub>)<sub>2</sub>O]<sub>5</sub>-(CH<sub>2</sub>)<sub>2</sub>-NH-C(O)-CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>2</sub>-[O(CH<sub>2</sub>)<sub>2</sub>]<sub>3</sub>-O-CH<sub>2</sub>-C(O)-NH-(CH<sub>2</sub>)<sub>4</sub>-; and  
-[(CH<sub>2</sub>)<sub>2</sub>O]<sub>3</sub>-(CH<sub>2</sub>)<sub>2</sub>-NH-C(O)-1,4-phenylene-NH-C(O)-CH<sub>2</sub>-S-CH<sub>2</sub>-.

In the description of the compounds of formula (I) the following definitions are used.

- 5 The term (1-8C)alkyl means a branched or unbranched alkyl group having 1-8 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, hexyl and octyl. Methyl and ethyl are preferred alkyl groups.

The term (1-8C)alkoxy means an alkoxy group having 1-8 carbon atoms, the alkyl moiety having the meaning as previously defined. Methoxy is a preferred alkoxy group.

- 10 The term (3-8C)cycloalkyl means a cycloalkyl group having 3-8 carbon atoms, being cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclo-octyl. Cyclopentyl and cyclohexyl are preferred cycloalkyl groups.

The spacer length is the number of atoms of the spacer, counted along the shortest chain between Z and the peptide part of the molecule, not counting the oxygen atom of the

- 15 oligosaccharide Z which is connected to the spacer.

The term "prodrug" means a compound of the invention in which the amino group of the amidino-moiety is protected, e.g. by hydroxy or a (1-6C)alkoxycarbonyl group.

- The compounds of the present invention are prepared by derivatizing NAPAP (or a NAPAP-analogue) at the glycine position with cysteine or lysine using methods generally known in the  
20 art, which compound subsequently (a) is coupled to a oligosaccharide-spacer residue or (b) is coupled to a spacer, which then is derivatized with a thiol group and subsequently is coupled to an oligosaccharide residue. Any suitable oligosaccharide may be used for this purpose, for example oligosaccharides known in literature (e.g. from EP 0,454,220 and EP 0,529,715, but  
25 not limited to these sources) or commercially available oligosaccharides. The oligosaccharides may be phosphorylated at an appropriate time by methods e.g. described by Buijsman, R. et al. (Abstracts of papers, 9th European Carbohydrate Symposium Utrecht 1997, Abstract A150). The coupling of the spacer to the oligosaccharide can for instance be performed by using the methods described in EP 0,649,854.

The peptide coupling, a procedural step in the above described method to prepare the compounds of the invention, can be carried out by methods commonly known in the art for the coupling - or condensation - of peptide fragments such as by the azide method, mixed anhydride method, activated ester method, or, preferably, by the carbodiimide method, especially with the  
5 addition of catalytic and racemisation suppressing compounds like N-hydroxysuccinimide and N-hydroxybenzotriazole. An overview is given in The Peptides, Analysis, Synthesis, Biology, Vol 3, E. Gross and J. Meienhofer, eds. (Academic Press, New York, 1981).

Amine functions present in the compounds may be protected during the synthetic procedure by  
10 an N-protecting group, which means a group commonly used in peptide chemistry for the protection of an  $\alpha$ -amino group, like the *tert*-butoxycarbonyl (Boc) group, the benzyloxycarbonyl (Z) group, the 9-fluorenylmethyloxycarbonyl (Fmoc) group or the phthaloyl (Phth) group. Removal of the protecting groups can take place in different ways, depending on the nature of those protecting groups. Usually deprotection takes place under acidic conditions  
15 and in the presence of scavengers. An overview of amino protecting groups and methods for their removal is given in the above mentioned The Peptides, Analysis, Synthesis, Biology, Vol 3.

The compounds of the invention, which can occur in the form of a free base, may be isolated from the reaction mixture in the form of a pharmaceutically acceptable salt. The pharmaceutically  
20 acceptable salts may also be obtained by treating the free base of formula (I) with an organic or inorganic acid such as HCl, HBr, HI, H<sub>2</sub>SO<sub>4</sub>, H<sub>3</sub>PO<sub>4</sub>, acetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, methanesulphonic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like.

25 The compounds of this invention possess chiral carbon atoms, and may therefore be obtained as a pure enantiomer, or as a mixture of enantiomers, or as a mixture containing diastereomers. Methods for obtaining the pure enantiomers are well known in the art, e.g. crystallization of salts which are obtained from optically active acids and the racemic mixture, or chromatography using chiral columns. For diastereomers straight phase or reversed phase columns may be used.



The compounds of the invention may be administered enterally or parenterally. The exact dose and regimen of these compounds and compositions thereof will necessarily be dependent upon the needs of the individual subject to whom the medicament is being administered, the degree of affliction or need and the judgment of the medical practitioner. In general parenteral  
5 administration requires lower dosages than other methods of administration which are more dependent upon absorption. However, the daily dosages are for humans preferably 0.001-100 mg per kg body weight, more preferably 0.01-10 mg per kg body weight.

The medicament manufactured with the compounds of this invention may also be used as adjuvant in acute anticoagulant therapy. In such a case, the medicament is administered with  
10 other compounds useful in treating such disease states.

Mixed with pharmaceutically suitable auxiliaries, e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture) the compounds may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or  
15 suppositories. By means of pharmaceutically suitable liquids the compounds can also be applied in the form of a solution, suspension, emulsion, e.g. for use as an injection preparation, or as a spray, e.g. for use as a nasal spray.

For making dosage units, e.g. tablets, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable  
20 additive which does not interfere with the function of the active compounds can be used.

Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts.

The invention is further illustrated by the following examples.

### EXAMPLES

5 Abbreviations used :

DMAPI = N,N-dimethylaminopyridine

TEA = triethylamine

Z = benzyloxycarbonyl

Ac = acetyl

10 MMTTr = monomethoxytrityl

Bn = benzyl

DCHA = dicyclohexylammonium

EDCI = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

HOBt = 1-hydroxybenzotriazole

15 DiPEA = diisopropylethylamine

Pyr = pyridinyl

TEG = tetraethylene glycol

HEG = hexaethylene glycol

APA = amidinophenylalanine

20 Cys = cysteine

The numbers of the compounds refer to the compounds on the formula sheets.

25 **4-O-(4-O-(2,3,4,6-tetra-O-acetyl- $\alpha$ -D-glucopyranosyl)-2,3,6-tri-O-acetyl- $\alpha$ -D-glucopyranosyl)-2,3,6-tri-O-acetyl- $\alpha$ / $\beta$ -D-glucopyranosyl trichloroacetimidate (4)**

To a stirred solution of maltotriose (1) (2.0 g, 4.0 mmol) in pyridine (100 mL) was added acetic anhydride (6.2 mL, 65 mmol) and a catalytic amount of DMAPI (0.79 g, 6.5 mmol). After 5 h the reaction mixture was poured into aqueous sodium hydrogencarbonate (1 M, 250 mL) and extracted three times with ethyl acetate (200 mL). The combined organic layers were dried on  
30 magnesium sulfate and concentrated *in vacuo*. The product was purified by column chromatography (light petroleum/ethyl acetate, 1/1 to 0/1, v/v) giving 2 as a white foam (91%

yield, 3.5 g). Anomeric deacetylation was achieved by treatment of **2** (3.0 g, 3.1 mmol) with 0.1 M solution of hydrazine acetate in dimethylformamide (34 mL, 3.4 mmol) for 1 h. After concentration *in vacuo* the reaction mixture was diluted with ethyl acetate (50 mL), washed with sodium hydrogencarbonate (1 M, 3 x 25 mL), dried (magnesium sulfate) and concentrated.

5 Purification by silica gel column chromatography (light petroleum/ethyl acetate, 3/2 to 1/0, v/v) gave **3** (92% yield, 2.7 g). Compound **3** (2.7 g, 3.1 mmol) was dissolved in dichloromethane (15 mL) and trichloroacetonitrile (1.7 mL) together with a catalytic amount of cesium carbonate (0.2 g, 0.62 mmol) were added. After 1 h the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. Purification of the crude **4** by column chromatography

10 (light petroleum/ethyl acetate/TEA, 50/49/1 to 0/99/1, v/v/v) yielded pure **4** as white foam (1.9 g, 71%).

***N*-Benzyloxycarbonyl-1-aminohexaethylene glycol 4-*O*-(4-*O*-(2,3,4,6-tetra-*O*-acetyl- $\alpha$ -D-glucopyranosyl)-2,3,6-tri-*O*-acetyl- $\alpha$ -D-glucopyranosyl)-2,3,6-tri-*O*-acetyl- $\beta$ -D-glucopyranoside (**6**)**

15 A solution of donor **4** (0.69 g, 0.76 mmol) and acceptor **5** (0.31 g, 0.76 mmol) in dichloromethane (1.5 mL) was stirred for 1 h under a flow of argon in the presence of activated molecular sieves 4Å (250 mg). The solution was cooled to -20 °C and a solution of trimethylsilyl trifluoromethanesulfonate (15  $\mu$ L) in dichloromethane (0.6 mL) was added dropwise to the

20 reaction mixture. After 10 min, TLC analysis (5% methanol in dichloromethane) showed the presence of one product. Solid sodium hydrogencarbonate (0.3 g) was added to the reaction mixture, which was stirred for 10 min and then filtrated. The filtrate was diluted with dichloromethane (50 mL), subsequently washed with aqueous sodium hydrogencarbonate (1 M, 2 x 25 mL), dried (magnesium sulfate), and concentrated *in vacuo*. The residue was

25 chromatographed on silica gel (0-4 % methanol in ethyl acetate) yielding pure **6** (0.57 g, 56% yield).

***N*-Benzyloxycarbonyl-1-aminohexaethylene glycol 4-*O*-(4-*O*-( $\alpha$ -D-glucopyranosyl)- $\alpha$ -D-glucopyranosyl)- $\beta$ -D-glucopyranoside (**7**)**

30 Compound **6** (0.57 g, 0.43 mmol) was treated with a solution of potassium *tert*-butoxide (43 mg, 10 mg per mmol Ac) in methanol (15 mL). After 1 h TLC analysis (ethyl acetate/pyridine/acetic

acid/water, 5/7/4/1.6, v/v/v/v) indicate a complete conversion of 6 into 7. The reaction was neutralized with Dowex 50 WX4-H<sup>+</sup> resin. The resin was removed by filtration and the filtrate was concentrated under reduced pressure to afford 7 (0.37 g, 95% yield), which was used without further purification.

5

***N*-Benzyloxycarbonyl-1-aminohexaethylene glycol 4-*O*-(4-*O*-( $\alpha$ -D-glucopyranosyl-2,3,4,6-tetrakis-(dibenzylphosphate))- $\alpha$ -D-glucopyranosyl-2,3,6-tris(dibenzylphosphate))- $\beta$ -D-glucopyranoside 2,3,6-tris(dibenzylphosphate) (9)**

A solution of 1*H*-tetrazole (54 mg, 0.77 mmol) in acetonitril (1 mL) was added to a mixture of 7 (86 mg, 95  $\mu$ mol) and 8 (450 mg, 1.4 mmol) in acetonitril/dioxane (2/1, v/v, 2 mL). After stirring for 1 h at 20 °C, the reaction mixture was cooled with an ice bath and *tert*-butylhydroperoxide (0.75 mL) was added. Stirring was continued for 45 min, after which TLC analysis showed the presence of one main product. Purification by silica gel column chromatography (100/0 to 95/5, dichloromethane/methanol, v/v) furnished pure 9 (311 mg, 92% yield).

15

**1-Aminohexaethylene glycol 4-*O*-(4-*O*-( $\alpha$ -D-glucopyranosyl 2,3,4,6-tetrakis phosphate)- $\alpha$ -D-glucopyranosyl 2,3,6-triphosphate)- $\beta$ -D-glucopyranoside 2,3,6-triphosphate (10)**

Compound 9 (311 mg, 87  $\mu$ mol) was dissolved in *tert*-butanol/water (6/1, v/v, 20 mL) containing a few drops of acetic acid. The solution was stirred under a continuous stream of hydrogen in the presence of 10% Pd/C (100 mg). After 3 h the Pd/C catalyst was removed by filtration and the filtrate was concentrated *in vacuo*. Dowex 50 WX4-Na<sup>+</sup> ion-exchange then furnished 10 (179 mg, 98 % yield).

20

**25 *N*-2-Naphtalenesulfonyl-*S*-4-monomethoxytrityl-(L)-cysteine (12)**

To a stirred mixture of commercially available *S*-4-monomethoxytrityl-(L)-cysteine (11) (0.34 g, 1 mmol), dioxane (5 mL) and 10 % aqueous sodium carbonate (5 mL) was added 2-naphtalenesulfonyl chloride (0.25 g, 1.1 mmol). After stirring for 1 h, the reaction mixture was acidified by addition of 5 % aqueous citric acid (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried (magnesium sulfate) and concentrated under reduced pressure. The crude product was chromatographed on silica gel

30

(methanol/dichloromethane/ triethylamine, 0/99/1 to 4/95/1, v/v/v) to yield **12** (76% yield, 0.44 g).

***N*-2-Naphtalenesulfonyl-*S*-2-pyridinesulfenyl-(*L*)-cysteine (**14**)**

- 5 A solution of trifluoroacetic acid and triisopropylsilane in dichloromethane (1/1/18, v/v/v) was added to compound **12** (0.44 g, 0.76 mmol). After stirring for 20 min, the mixture was poured into water and extracted with dichloromethane (2 x 50 mL). The combined organic layers were dried on magnesium sulfate and concentrated *in vacuo*. Traces of trifluoroacetic acid in the crude mixture were removed by coevaporation with toluene. The resulting free thiol **13** was
- 10 redissolved in isopropanol (2.5 mL) and added dropwise to a solution of Aldrithiol™ (1.7 g, 7.6 mmol) in isopropanol/2 N aqueous acetic acid (1/1, v/v, 20 mL). After 1 h, TLC analysis indicated the reaction to be complete and the mixture was concentrated under reduced pressure. Traces of acetic acid in the residue were removed by coevaporation with toluene. The crude product was dissolved in acetone (10 mL) and to this solution dicyclohexylamine (0.3 mL) was
- 15 added, afterwhich compound **14** precipitated from the reaction mixture as its DCHA-salt. The precipitate was isolated, dissolved in ethyl acetate (50 mL) and washed with 5 % aqueous citric acid (2 x 30 mL). The organic layer was dried (magnesium sulfate) and concentrated under reduced pressure to afford pure **14** (55 % yield, 0.25 g).

20 ***N*-(*N*<sup>α</sup>-2-Naphtalenesulfonyl-*S*-2-pyridinesulfenyl-(*L*)-cysteinyl)-(*D,L*)-4-amidinophenylalanyl) piperidine (**16**)**

- To a solution of *N*-((*D,L*)-4-amidinophenylalanyl)piperidine dihydrochloride (**15**) (0.13 g, 0.39 mmol) and cysteine derivative **14** (0.16 g, 0.39 mmol) in dimethylformamide (2 mL) was added HOBt (58 mg, 0.42 mmol), EDCI (82 mg, 0.42 mmol) and *N*-ethylmorpholine (110 μL, 0.78
- 25 mmol). After stirring for 16 h, the mixture was diluted with dichloromethane (20 mL) and washed with water (2 x 10 mL). The organic layer was dried (magnesium sulfate) and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (first 10%-20 % methanol in dichloromethane to remove impurities and then ethyl acetate/pyridine/acetic acid/water (16/7/1.6/4, v/v/v/v) to release product) and subsequently by gel filtration on
- 30 Sephadex LH-20 (eluent: methanol/dichloromethane, 4/1, v/v) to yield homogeneous **16** (70%, 0.19 g).

**Condensation coupling of maltotriose-decaphosphate 18 with peptide 16**

To a solution of maltotriose-decaphosphate **18** (21 mg, 9.8  $\mu\text{mol}$ ) in 0.1 M  $\text{Na}_2\text{HPO}_4$  buffer (1.0 mL, pH 7.5) was added a solution of *N*-hydroxysuccinimidyl-2-bromoacetate in methanol (1 mL). After stirring for 2 h, the reaction mixture was applied on a Sephadex G25 column eluted with 10% acetonitril in water. The appropriate fractions were pooled and concentrated under reduced pressure at low temperature (25 °C) to yield compound **19**. NAPAP analogue **16** (10 mg, 15  $\mu\text{mol}$ ) was dissolved in a mixture of methanol (1 mL) and 0.1 M  $\text{Na}_2\text{HPO}_4$  buffer (0.75 mL, pH 7.0) degassed by passing through helium and by sonification. To this solution tributylphosphine (4.1  $\mu\text{L}$ , 16  $\mu\text{mol}$ ) was added and the reaction mixture was stirred under an argon atmosphere. After 1 h HPLC analysis (Lichrospher<sup>®</sup> RP18-column) indicated a complete cleavage of the 2-pyridinesulfonyl group and a solution of compound **19** in dimethylformamide (0.25 mL) and 0.1 M  $\text{Na}_2\text{HPO}_4$  buffer (0.50 mL, pH 7.0) was added to the reaction mixture. The mixture was stirred for 3 h, after which the crude mixture was purified by gel filtration (Fractogel HW-40, eluent: 0.15 M TEAB). Concentration of the appropriate fractions and subsequent Dowex 50 WX- $\text{Na}^+$  ion-exchange gave after lyophilization homogeneous conjugate **I** (10.1 mg, 47% yield). The two diastereoisomers were separated by semi-preparative HPLC column chromatography (LiChrospher<sup>®</sup> RP-18 column, gradient: 17.5%-22.5%  $\text{CH}_3\text{CN}$  in 0.05 M aqueous TEAA) to give diastereoisomer **I-a** (retention time: 28.6 min) and diastereoisomer **I-b** (retention time: 33.0 min). The two isomers were desalted by gel filtration (Sephadex G-25 DNA-grade Superfine), transformed into the  $\text{Na}^+$ -form using Dowex 50 WX- $\text{Na}^+$  ion exchange resin.

Diastereoisomer **I-a**:  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ , 600 MHz, HH-COSY): *maltotriose*: (reducing end) 4.65 (bs, 1H, H1), 3.85 (m, 1H, H2), 4.35 (m, 1H, H3), 3.76 (m, 1H, H4); 5.50 (bs, 1H, H1'), 4.18 (m, 1H, H2'), 4.10 (m, 1H, H4'); (non-reducing end) 5.71 (bs, 1H, H1''), 4.09 (m, 1H, H2''), 4.45 (m, 1H, H3''), 4.15 (m, 1H, H4''); 3.95-3.84 (H5, maltotriose); *spacer*: 3.65-3.51 (m, 22H,  $\text{OCH}_2$  HEG), 3.35 (m, 2H,  $\text{CH}_2\text{NH}_2$ ), 3.15 (s, 2H,  $\text{SCH}_2(\text{O})$ ); *peptide*: 8.31 (s, 1H,  $\text{H}_{\text{arom}}$  NAS), 8.06-7.67 (m, 6H,  $\text{H}_{\text{arom}}$  NAS), 7.70, 7.17 (2 x d, 4H,  $\text{H}_{\text{arom}}$  APA,  $J=7.8$  Hz), 4.28 (m, 1H,  $\alpha\text{CH}$  APA), 3.91 (m, 1H,  $\alpha\text{CH}$  Cys), 3.30-3.04 (m, 4H,  $\text{CH}_2\text{N}$  piperidine), 2.82-2.62 (m, 3H,  $\beta\text{CH}_2$  Cys,  $\beta\text{CH}$  APA), 2.57 (m, 1H,  $\beta\text{CH}'$  APA), 1.45-1.25 (m, 6H,  $\text{CH}_2$  piperidine); ES-MS:  $[\text{M}-3\text{H}]^{3+}$  724.1,  $[\text{M}-2\text{H}]^{2+}$  1086.7.

Diastereoisomer I-b:  $^1\text{H}$  NMR ( $\text{D}_2\text{O}$ , 600 MHz, HH-COSY): *maltotriose*: (reducing end) 3.80 (m, 1H, H2), 4.32 (m, 1H, H3), 3.89 (m, 1H, H4); 5.49 (bs, 1H, H1'), 4.22 (m, 1H, H2'), 4.11 (m, 1H, H4'); (non-reducing end) 5.70 (bs, 1H, H1''), 4.22 (m, 1H, H2''), 4.52 (m, 1H, H3''), 4.24 (m, 1H, H4''); 3.91-3.84 (H5, maltotriose); *spacer*: 3.63-3.52 (m, 22H,  $\text{OCH}_2$  HEG), 3.35 (t, 2H,  $\text{CH}_2\text{NH}_2$ ), 3.17 (AB, 2H,  $\text{SCH}_2(\text{O})$ ); *peptide*: 8.35 (s, 1H,  $\text{H}_{\text{arom}}$  NAS), 8.07-7.65 (m, 6H,  $\text{H}_{\text{arom}}$  NAS), 7.77, 7.22 (2 x d, 4H,  $\text{H}_{\text{arom}}$  APA,  $J=7.8$  Hz), 4.62 (t, 1H,  $\alpha\text{CH}$  APA,  $J_{\alpha\text{CH},\beta\text{CH}}=7.3$  Hz), 4.05 (m, 1H,  $\alpha\text{CH}$  Cys), 3.05-3.00 (m, 4H,  $\text{CH}_2\text{N}$  piperidine), 2.85-2.67 (m, 4H,  $\beta\text{CH}_2$  Cys,  $\beta\text{CH}_2$  APA), 1.88-1.24 (m, 6H,  $\text{CH}_2$  piperidine); ES-MS:  $[\text{M}-3\text{H}]^3-$  724.0,  $[\text{M}-2\text{H}]^2-$  1086.2.

10

***N*-Hydroxysuccinimidyl-14-*S*-2-pyridinesulfenyl-14-mercapto-3,6,9,12-tetraoxatetra-decanoate (22)**

Spacer **20** (0.75, 2.4 mmol) (P. Westerduin et al., Angew. Chem. Int. Ed. Engl. 1996, 35, 3, p331-333) and Aldrithiol<sup>TM</sup> (2.6 g, 12.1 mmol) was dissolved in dichloromethane (20 mL) and treated with *n*-butylamine (4 mL). After stirring for 2 h, the reaction mixture was concentrated *in vacuo*, redissolved in dichloromethane (50 mL) and washed with 5% aqueous citric acid (2 x 50 mL). The organic layer was dried and concentrated under reduced pressure. Silica gel column chromatography (methanol/acetic acid/dichloromethane, 0/1/99 to 6/1/93, v/v/v) of the residue yielded pure **21** (0.80 g, 88% yield). Compound **21** (0.80 g, 2.1 mmol) was dissolved in dichloromethane (10 mL) and *N*-hydroxysuccinimide (0.26 g, 2.3 mmol) and EDCI (0.45 mg, 2.3 mmol) were added to this solution. After 1 h, the reaction mixture was diluted with dichloromethane (50 mL), washed three times with ice water (20 mL), dried (magnesium sulfate) and concentrated to give **22** (0.98 mg, 98% yield), which was used without further purification.

***N*<sup>ε</sup>-*tert*-Butyloxycarbonyl-*N*<sup>α</sup>-benzenesulfonyl-(L)-lysine (24)**

Prepared as described for **12**, using **23** and benzenesulfonyl chloride as starting materials. (0.86 g, 75% yield).

***N*<sup>ε</sup>-(14-*S*-2-Pyridinesulfenyl-14-mercapto-3,6,9,12-tetraoxatetradecanoyl)-*N*<sup>α</sup>-benzenesulfonyl-(L)-lysine (26)**

30

Compound **24** (0.86 g, 2.2 mmol) was treated with 3 N hydrogen chloride in ethyl acetate. After 15 min the reaction mixture was concentrated *in vacuo*. Traces of acid in the residue were removed by coevaporation with toluene. The crude **25** was dissolved in a mixture of dioxane/water (4/1, v/v, 2.5 mL) and to this solution compound **22** (0.98 g, 2.1 mmol) and DiPEA (1.1 mL, 6.6 mmol) were added. After 1 h, the reaction mixture was diluted with dichloromethane (100 mL) and washed with 5 % aqueous citric acid (2 x 50 mL). The organic layer was dried (magnesium sulfate) and concentrated *in vacuo*. The residual oil was purified by silica gel column chromatography (0-10% methanol/ethyl acetate) to give homogeneous **26** (0.95 g, 67% yield).

***N*(*N*'-(14-*S*-2-Pyriminesulfonyl-14-mercapto-3,6,9,12-tetraoxatetradecanoyl)-*N*<sup>α</sup>-benzenesulfonyl-(*L*)-lysiny)-(D,L)-4-amidinophenylalanyl)piperidine (27)**

Prepared as described for **16**, using **26** and **15** as starting materials. (87 mg, 70% yield).

**15 Condensation coupling of maltotriose-decaphosphate **18** with peptide **27** (II)**

Prepared as described for **I**, using **18** and **27** as starting materials. Purification of the crude **II** was effected by semi-preparative HPLC (LiChrospher® RP-18 column). Subsequent desalting by gel filtration (Sephadex G-25 DNA-grade Superfine), transformation into the Na<sup>+</sup>-form using Dowex 50 WX4-Na<sup>+</sup> ion exchange resin and lyophilization afforded pure **II** as a white fluffy solid (8.5 mg, 23% yield from **18**).

<sup>1</sup>H NMR (D<sub>2</sub>O, 600 MHz, HH-COSY): **maltotriose**: (reducing end) 4.67 (m, 1H, H1), 4.07 (m, 1H, H2), 4.40 (m, 1H, H3), 4.06 (m, 1H, H4); 5.49 (bs, 1H, H1'), 4.24 (m, 1H, H2'), 4.66 (m, 1H, H3'), 4.10 (m, 1H, H4'); (non-reducing end) 5.73 (bs, 1H, H1''), 4.17 (m, 1H, H2''), 4.38 (m, 1H, H3''), 4.22 (m, 1H, H4''); 3.95-3.82 (H5, maltotriose); **spacer**: 4.03, 4.02 (2 x s, 2H, OCH<sub>2</sub>C(O)), 3.73-3.59 (m, 36H, OCH<sub>2</sub> TEG, HEG), 3.38 (t, 2H, CH<sub>2</sub>NH<sub>2</sub>), 3.27, 3.26 (2 x s, 2H, SCH<sub>2</sub>(O)), 2.75 (2 x t, 2H, CH<sub>2</sub>S); **peptide**: 7.81-7.52 (m, 5H, H<sub>arom</sub> BS), 7.79, 7.76, 7.42, 7.41, (4 x d, 4H, H<sub>arom</sub> APA), 4.87, 4.66 (2 x t, 1H, αCH APA, *J*<sub>αCH,βCH</sub>=7.4 Hz), 4.07 (m, 1H, αCH Lys), 3.37-3.73 (m, 8H, εCH<sub>2</sub> Lys, βCH<sub>2</sub> APA, CH<sub>2</sub>N piperidine), 1.96-1.46 (m, 12H, CH<sub>2</sub> piperidine, β/γ,δCH<sub>2</sub> Lys);

ES-MS: [M+3H]<sup>3+</sup> 801.2, [M+2H]<sup>2+</sup> 1200.8.



**Partially protected pentasaccharide 30**

Known pentasaccharide **29** (53 mg, 49  $\mu$ mol) (R.C. Buijsman et al., Chem. Eur. J. 1996, 2, 12, p1572-1577) was dissolved in dimethylformamide (0.25 mL) and water (1 mL) and treated with *N*-(benzyloxycarbonyloxy)-succinimide (18 mg, 72  $\mu$ mol) and *N*-ethylmorpholine (18.6 mL).  
5 After stirring for 15 min, TLC analysis (ethyl acetate/pyridine/acetic acid/water, 5/7/1.6/4, v/v/v/v) revealed the reaction to be complete and the reaction mixture was directly applied onto a RP-18 column, which was eluted with water/methanol (90/10 to 60/40). The appropriate fractions were pooled and concentrated to a small volume and applied on a Dowex 50 WX4-H<sup>+</sup> ion-exchange column in water. The eluate was concentrated *in vacuo* to yield pure **30** (54 mg,  
10 91% yield).

**Sulfated pentasaccharide 32**

Compound **30** (54 mg, 45  $\mu$ mol) was dissolved in dimethylformamide (1 mL). Triethylamine sulfurtrioxide complex (0.51 g, 5 equiv for each hydroxyl group) was added and the mixture was  
15 stirred under a nitrogen atmosphere at 55 °C for 16 h. The mixture was subsequently cooled to 0 °C and aqueous sodium hydrogen carbonate was added (5 equiv for each eq. of triethylamine sulfurtrioxide complex). The mixture was stirred for 1 h, concentrated to a small volume and applied onto a Sephadex G-25 column, which was eluted with 10 % acetonitril in water. The appropriate fractions were pooled and concentrated to a small volume, which was subsequently  
20 passed through a column of Dowex 50 WX4 (Na<sup>+</sup> form) eluted with water. The eluate was concentrated and redissolved in 0.2 N hydrogen chloride (1 mL) and allowed to stand for 16 h at 4 °C. The reaction mixture was neutralized with 0.1 N sodium hydroxide and desalted on a Sephadex G-25 column and eluted with 10 % acetonitril in water to afford homogeneous **31**. Compound **31** was dissolved in *tert*-butanol/water (6/1, v/v, 20 mL) containing a few drops of  
25 acetic acid. The solution was stirred under a continuous stream of hydrogen in the presence of 10 % Pd/C (100 mg). After 3 h the Pd/C catalyst was removed by filtration and the filtrate was concentrated *in vacuo* to furnish pure **32** (60 mg, 60% yield).

**Condensation coupling of pentasaccharide 32 with peptide 16**



30 Pentasaccharide **32** (15 mg, 6.5  $\mu$ mol) was dissolved in 0.1 M NaH<sub>2</sub>PO<sub>4</sub> buffer (2 mL, pH 7.5) and to this solution was added *sulfo*-SIAB<sup>TM</sup> (16 mg, 33  $\mu$ mol). After stirring 3 h in the dark,


HPLC analysis (monoQ anion exchange) revealed the reaction to be complete and the crude **34** was purified on a Superdex 30 column (10% acetonitril in water). The appropriate fractions were pooled and concentrated *in vacuo* at low temperature (25 °C). To a solution of NAPAP analogue **16** (9 mg, 14 µmol) in a mixture of methanol (1 mL) and 0.1 M Na<sub>2</sub>HPO<sub>4</sub> buffer (0.75 mL, pH 7.0), degassed by passing through helium and by sonification before use, was added tributylphosphine (3.9 µL, 15 µmol). After stirring for 1 h under an argon atmosphere, HPLC analysis (Lichrospher® RP-18 column) indicated a complete cleavage of the 2-pyridinesulfenyl group. A solution of derivatized pentasaccharide **34** in dimethylformamide (0.25 mL) and 0.1 M Na<sub>2</sub>HPO<sub>4</sub> buffer (0.50 mL, pH 7.0) was added and the mixture was stirred for 3 h. The crude product was applied onto a Sephadex G-50 column, which was eluted with 10 % acetonitril in water. The appropriate fractions were pooled, concentrated to a small volume and desalted on a Superdex 30 column, which was eluted with 10 % methanol in water. Concentration and lyophilization yielded conjugate **III** as a white solid (9 mg, 52 % yield).

<sup>1</sup>H NMR (D<sub>2</sub>O, 600 MHz, HH-COSY): δ 3.60, 3.53, 3.43 (3 x s, 9H, CH<sub>3</sub>O<sub>E,G,H</sub>); **ring D**: 5.53 (m, 1H, H1), 4.15 (m, 1H, H2), 4.58 (m, 1H, H3), 3.56 (m, 1H, H4), 3.92 (m, 1H, H5), 4.26, 4.13 (2 x m, 2H, H6, H6'); **ring E**: 4.70 (d, 1H, H1, *J*<sub>1,2</sub>=8.1 Hz), 4.21 (m, 1H, H2), 3.62 (m, 1H, H3), 3.92 (m, 1H, H4), 3.74 (m, 1H, H5); **ring F**: 5.39 (d, 1H, H1, *J*<sub>1,2</sub>=3.8 Hz), 4.22 (m, 1H, H2), 4.56 (m, 1H, H3), 3.83 (t, 1H, H4, *J*<sub>3,4</sub>=*J*<sub>4,5</sub>=9.8 Hz), 4.12 (m, 1H, H5); **ring G**: 5.15 (bs, 1H, H1), 4.35 (m, 1H, H2), 3.76 (m, 1H, H3), 4.21 (m, 1H, H4), 4.80 (m, 1H, H5); **ring H**: 5.10 (d, 1H, H1, *J*<sub>1,2</sub>=3.6 Hz), 4.31 (m, 1H, H2), 4.54 (m, 1H, H3), 4.21 (m, 1H, H4); **spacer**: 7.51, 7.53, 7.13, 7.12 (4 x d, 4H, H<sub>arom</sub> SIAB), 3.73 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 3.66 (m, 12H, OCH<sub>2</sub> TEG), 3.31 (m, 2H, CH<sub>2</sub>NH<sub>2</sub>); **peptide**: 8.27, 8.22 (2 x s, 1H, H<sub>arom</sub> NAS), 7.98-7.60 (m, 6H, H<sub>arom</sub> NAS), 7.71, 7.64, 7.46, 7.44 (4 x d, 4H, H<sub>arom</sub> APA), 4.60, 4.45 (2 x t, 1H, αCH APA, *J*<sub>αCH,βCH</sub>=6.6 Hz), 4.00, 3.97 (2 x m, 1H, αCH Cys), 3.10-2.85 (m, 4H, CH<sub>2</sub>N piperidine), 2.82-2.70 (m, 3H, βCH<sub>2</sub> Cys, βCH APA), 2.61 (m, 1H, βCH' APA), 1.55-1.15 (m, 6H, CH<sub>2</sub> piperidine);

ES-MS: [M-H]<sup>-</sup> 2680.6

Using similar methods, the following compounds are prepared:





- 5 The biological activities of the compounds of the present invention were determined by the following test methods.

#### I. Anti-thrombin assay

Thrombin (Factor IIa) is a factor in the coagulation cascade.

- 10 The anti-thrombin activity of compounds of the present invention was assessed by measuring spectrophotometrically the rate of hydrolysis of the chromogenic substrate s-2238 exerted by thrombin. This assay for anti-thrombin activity in a buffer system was used to assess the IC<sub>50</sub> value of a test compound.

- 15 Test medium: Tromethamine-NaCl-polyethylene glycol 6000 (TNP) buffer

Reference compound: I2581 (Kabi)

Vehicle: TNP buffer.

Solubilisation can be assisted with dimethylsulphoxide, methanol, ethanol, acetonitrile or tert.-butyl alcohol which are without adverse effects in concentrations up to 2.5% in the final reaction mixture.

TechniqueReagents\*

## 1. Tromethamine-NaCl (TN) buffer

## Composition of the buffer:

	Tromethamine (Tris)	6.057 g	(50 mmol)
5	NaCl	5.844 g	(100 mmol)
	Water to	1	l

The pH of the solution is adjusted to 7.4 at 37 °C with HCl (10 mmol·l<sup>-1</sup>).

## 2. TNP buffer

10 Polyethylene glycol 6000 is dissolved in TN buffer to give a concentration of 3 g·l<sup>-1</sup>.

## 3. S-2238 solution

One vial S-2238 (25 mg; Kabi Diagnostica, Sweden) is dissolved in 20 ml TN buffer to give a concentration of 1.25 mg·ml<sup>-1</sup> (2 mmol·l<sup>-1</sup>).

## 15 4. Thrombin solution

Human thrombin (16 000 nKat·vial<sup>-1</sup>; Centraal Laboratorium voor Bloedtransfusie, Amsterdam, The Netherlands) is dissolved in TNP buffer to give a stock solution of 835 nKat·ml<sup>-1</sup>.

20 Immediately before use this solution is diluted with TNP buffer to give a concentration of 3.34 nKat·ml<sup>-1</sup>.

- \* - All ingredients used are of analytical grade
- For aqueous solutions ultrapure water (Milli-Q quality) is used.

25 Preparation of test and reference compound solutions

The test and reference compounds are dissolved in Milli-Q water to give stock concentrations of 10<sup>-2</sup> mol·l<sup>-1</sup>. Each concentration is stepwise diluted with the vehicle to give concentrations of 10<sup>-3</sup>, 10<sup>-4</sup> and 10<sup>-5</sup> mol·l<sup>-1</sup>. The dilutions, including the stock solution, are used in the assay (final concentrations in the reaction mixture: 3·10<sup>-3</sup>; 10<sup>-3</sup>; 3·10<sup>-4</sup>; 10<sup>-4</sup>; 3·10<sup>-5</sup>; 10<sup>-5</sup>; 3·10<sup>-6</sup> and 10<sup>-6</sup> mol·l<sup>-1</sup>, respectively).

30

### Procedure

At room temperature 0.075 ml and 0.025 ml test compound or reference compound solutions or vehicle are alternately pipetted into the wells of a microtiter plate and these solutions are diluted with 0.115 ml and 0.0165 ml TNP buffer, respectively. An aliquot of 0.030 ml S-2238 solution is added to each well and the plate is pre-heated and pre-incubated with shaking in an incubator (Amersham) for 10 min. at 37 °C. Following pre-incubation the hydrolysis of S-2238 is started by addition of 0.030 ml thrombin solution to each well. The plate is incubated (with shaking for 30 s) at 37 °C. Starting after 1 min of incubation, the absorbance of each sample at 405 nm is measured every 2 min. for a period of 90 min. using a kinetic microtiter plate reader (Twinreader plus, Flow Laboratories).

All data are collected in an IBM personal computer using LOTUS-MEASURE. For each compound concentration (expressed in  $\text{mol}\cdot\text{l}^{-1}$  reaction mixture) and for the blank the absorbance is plotted versus the reaction time in min.

Evaluation of responses: For each final concentration the maximum absorbance was calculated from the assay plot. The  $\text{IC}_{50}$ -value (final concentration, expressed in  $\mu\text{mol}\cdot\text{l}^{-1}$ , causing 50% inhibition of the maximum absorbance of the blank) was calculated using the logit transformation analysis according to Hafner et al. (Arzneim.-Forsch./Drug Res. 1977; 27(II): 1871-3).

### Antithrombin activity:

Example	$\text{IC}_{50}$ ( $\text{mol}\cdot\text{l}^{-1}$ )
I (one diastereomer)	$2 \times 10^{-7}$
II	$8 \times 10^{-6}$
III	$3.5 \times 10^{-7}$

## II. Anti-factor Xa assay

Activated Factor X (Xa) is a factor in the coagulation cascade. The anti-Xa activity of compounds of the present invention was assessed by measuring spectrophotometrically the rate of hydrolysis of the chromogenic substrate s-2222 exerted by Xa. This assay for anti-Xa activity in a buffer system was used to assess the IC<sub>50</sub>-value of the test compound.

In general the followed procedure and test conditions were analogous to those of the anti-thrombin assay as described above. Differences are indicated below.

Reference compound: benzamidine

Vehicle: TNP buffer.

Solubilisation can be assisted with dimethylsulphoxide, methanol, ethanol, acetonitrile or tert.-butyl alcohol which are without adverse effects in concentrations up to 1% (for DMSO) and 2.5% (for the other solvents) in the final reaction mixture.

### Technique

#### Reagents\*

#### 3. S-2222 solution

One vial S-2222 (15 mg; Kabi Diagnostica, Sweden) is dissolved in 10 ml water to give a concentration of 1.5 mg·ml<sup>-1</sup> (2 mmol·l<sup>-1</sup>).

#### 4. Xa solution

Bovine Factor Xa Human (71 nKat·vial<sup>-1</sup>; Kabi Diagnostica) is dissolved in 10 ml TNP buffer and then further diluted with 30 ml TNP buffer to give a concentration of 1.77 nKat·ml<sup>-1</sup>. The dilution has to be freshly prepared.

#### Procedure




Instead of the S-2238 solution (in anti-thrombin assay), the above S-2222 solution is added to each well in this assay.

## Anti-factor Xa activity


Example	U / mg
III	885








## FORMULA SHEET 1







## FORMULA SHEET 2



- i  $\rightarrow$  11  $R^6=H$ ,  $R^7=MMTr$   
ii  $\rightarrow$  12  $R^6=NAS$ ,  $R^7=MMTr$   
iii  $\rightarrow$  13  $R^6=NAS$ ,  $R^7=H$   
     $\rightarrow$  14  $R^6=NAS$ ,  $R^7=SPyr$




## FORMULA SHEET 3



## FORMULA SHEET 4




## FORMULA SHEET 5




CLAIMS

1. A compound of the formula (I)



- 5 wherein  $\text{R}^1$  is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy;
- $\text{R}^2$  and  $\text{R}^3$  are independently H or (1-8C)alkyl;
- 10  $\text{R}^4$  is (1-8C)alkyl or (3-8C)cycloalkyl;
- or  $\text{R}^3$  and  $\text{R}^4$  together with the nitrogen atom to which they are bonded are a nonaromatic (4-8)membered ring optionally containing another heteroatom, the ring optionally being substituted with (1-8C)alkyl or  $\text{SO}_2\text{-(1-8C)alkyl}$ ;
- $\text{Q}$  is a spacer having a chain length of 10 to 70 atoms; and
- 15  $\text{Z}$  is a negatively charged oligosaccharide residue comprising two to six monosaccharide units, the charge being compensated by positively charged counterions;
- or a pharmaceutically acceptable salt thereof or a prodrug thereof.
2. The compound of claim 1, wherein  $\text{Z}$  is derived from an oligosaccharide which has *per se*
- 20 AT-III mediated anti-Xa activity.
3. The compound of claim 2, wherein  $\text{Z}$  is a pentasaccharide residue.


4. The compound of claim 3, wherein Z has the formula (II)



wherein  $R^5$  is independently  $OSO_3^-$  or (1-8C)alkoxy.

5. The compound of any one of claims 1 to 4, wherein  $R^1$  is phenyl, 4-methoxy-2,3,6-trimethylphenyl or naphthyl;  $R^2$  is H; and  $NR^3R^4$  represents the piperidinyl group.

6. The compound of any one of claims 1 to 5, wherein Q has the formula (III)



wherein

W is  $-[1,4\text{-phenylene-NR}^3\text{-C(O)}]_q\text{-(CH}_2)_r\text{-S-}$

or

$-(CH_2)_t\text{-S-(CH}_2)_u\text{-[O(CH}_2)_2]_v\text{-O-(CH}_2)_w\text{-C(O)-NR}^3\text{-}$ ;

and  $R^3$  is independently H or (1-8C)alkyl;

$m = 1 - 12$ ;  $n = 1 - 8$ ;  $p = 0 - 4$ ;  $q = 0$  or 1;  $r = 1 - 8$ ;  $s = 1 - 8$ ;  $t = 1 - 8$ ;  $u = 1 - 8$ ;  $v = 1 - 12$ ;

$w = 1 - 8$ ; the total number of atoms is 10 - 70; and the moiety  $-[(CH_2)_2O]_m-$  is the end with which Q is attached to Z.

7. The compound of claim 6, wherein Q is selected from

$-[(CH_2)_2O]_5\text{-(CH}_2)_2\text{-NH-C(O)-CH}_2\text{-S-CH}_2\text{-}$ ;

$-[(CH_2)_2O]_5\text{-(CH}_2)_2\text{-NH-C(O)-CH}_2\text{-S-(CH}_2)_2\text{-[O(CH}_2)_2]_3\text{-O-CH}_2\text{-C(O)-NH-(CH}_2)_4\text{-}$ ; and

$-[(CH_2)_2O]_3\text{-(CH}_2)_2\text{-NH-C(O)-1,4-phenylene-NH-C(O)-CH}_2\text{-S-CH}_2\text{-}$ .

8. A pharmaceutical composition comprising the compound of any one of claims 1 to 7 and pharmaceutically suitable auxiliaries.
9. The compound of any one of claims 1 to 7 for use in therapy.
10. Use of the compound of any one of claims 1 to 7 for the manufacture of a medicament for treating or preventing thrombosis or other thrombin-related diseases.



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/04100

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K9/00 A61K38/14 C07H3/06 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 558 961 A (BEHRINGWERKE AG) 8 September 1993 (1993-09-08) cited in the application page 6, line 52 - page 7, line 14; claims 1,7	1-10
Y	EP 0 818 459 A (SANOFI SA ; AKZO NOBEL NV (NL)) 14 January 1998 (1998-01-14) page 2, line 1 - line 36	1-10
Y	EP 0 649 854 A (AKZO NOBEL NV ; SANOFI ELF (FR)) 26 April 1995 (1995-04-26) cited in the application claims 1-10	1-10
Y	EP 0 513 543 A (BEHRINGWERKE AG) 19 November 1992 (1992-11-19) claims 1,16,17	1-10
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 August 1999

Date of mailing of the international search report

23/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

# INTERNATIONAL SEARCH REPORT

International Publication No  
PCT/EP 99/04100

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 236 163 A (SANOFI SA) 9 September 1987 (1987-09-09) claims 1-24	1-10
Y	STUEBER W ET AL: "Inhibition of thrombin by derivatives of the dipeptide aspartic acid-amidinophenylalanine" PEPT.: CHEM., STRUCT. BIOL., PROC. AM. PEPT. SYMP., 13TH (60LXAW);94; PP.643-5, XP002084735 Behringwerke;Research Laboratories; Marburg; Germany (DE) the whole document	1-10
Y	WALTER E ET AL: "Transepithelial transport of four peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2)" PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (PCRMEY,10220178);94; VOL.21ST,; PP.712-13, XP002084736 University Marburg;Department Pharmaceutics and Biopharmacy; Marburg; 35037; Germany (DE) the whole document	1-10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Publication No

PCT/EP 99/04100

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0558961	A	08-09-1993	DE 4206858 A	09-09-1993
			AU 3395093 A	09-09-1993
			CA 2091024 A	06-09-1993
			CN 1077961 A	03-11-1993
			CZ 9203859 A	19-01-1994
			IL 104931 A	31-10-1996
			JP 6025291 A	01-02-1994
			MX 9301212 A	01-09-1993
			NZ 247043 A	28-08-1995
			US 5556941 A	17-09-1996
			ZA 9301538 A	27-09-1993
EP 0818459	A	14-01-1998	SG 46779 A	20-01-1998
			AU 2008697 A	13-11-1997
			BR 9703099 A	08-09-1998
			CA 2204204 A	08-11-1997
			CZ 9701386 A	18-02-1998
			HU 9700852 A	29-12-1997
			JP 10045805 A	17-02-1998
			NO 972120 A	10-11-1997
			NZ 314745 A	24-09-1998
			PL 319843 A	10-11-1997
			SG 55310 A	21-12-1998
			US 5872110 A	16-02-1999
			ZA 9703892 A	19-08-1998
EP 0649854	A	26-04-1995	AU 679084 B	19-06-1997
			AU 7161094 A	16-03-1995
			CA 2131229 A	02-03-1995
			FI 944001 A	02-03-1995
			HU 69163 A	28-08-1995
			JP 7304787 A	21-11-1995
			NO 943222 A	02-03-1995
			NZ 264340 A	27-04-1995
			US 5705489 A	06-01-1998
			ZA 9406673 A	21-04-1995
EP 0513543	A	19-11-1992	DE 4115468 A	12-11-1992
			AT 129503 T	15-11-1995
			AU 651196 B	14-07-1994
			AU 1608692 A	12-11-1992
			CA 2068263 A	12-11-1992
			CN 1067249 A, B	23-12-1992
			DE 59204094 D	30-11-1995
			DK 513543 T	26-02-1996
			ES 2079719 T	16-01-1996
			GR 3018182 T	29-02-1996
			HK 1006717 A	12-03-1999
			IE 68884 B	24-07-1996
			IL 101819 A	15-04-1997
			JP 2097129 C	02-10-1996
			JP 5155898 A	22-06-1993
			JP 8009634 B	31-01-1996
			MX 9202166 A	01-11-1992
			NZ 242668 A	27-06-1994
			RU 2088591 C	27-08-1997
			US 5457114 A	10-10-1995
			US 5627283 A	06-05-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 99/04100

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0236163 A	09-09-1987	FR 2593812 A	07-08-1987
		FR 2593814 A	07-08-1987
		AT 57179 T	15-10-1990
		CA 1307076 A	01-09-1992
		JP 62228050 A	06-10-1987
		PT 84170 A,B	01-02-1987
		US 4977168 A	11-12-1990
		AT 56429 T	15-09-1990
		CA 1312703 A	12-01-1993
		EP 0236164 A	09-09-1987
		PT 84171 A,B	01-02-1987
		US 4791102 A	13-12-1988